Clinical trial of levocarnitine injection combined with Shengxuening tablets in the treatment of diabetic nephropathy peritoneal dialysis patients with renal anemia
10.13699/j.cnki.1001-6821.2018.02.003
- VernacularTitle:左卡尼汀注射液联合生血宁片治疗糖尿病肾病腹膜透析伴肾性贫血的临床研究
- Author:
Jin ZHOU
1
;
Feng-Ling GUO
;
Lan HUANG
;
Gui-Cai HU
Author Information
1. 承德医学院附属医院肾内科
- Keywords:
Shengxuening tablet;
levocarnitine injection;
diabetic nephropathy;
peritoneal dialysis;
renal anemia
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(2):105-107,130
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of levocarnitine injection combined with Shengxuening tablets in the treatment of diabetic nephropathy peritoneal dialysis patients with renal anemia.Methods A total of 30 diabetic nephropathy peritoneal dialysis patients with renal anemia were randomly divided into control group and treatment group with 15 cases per group.Control group was given recombinant human erythropoietin injection 100-150 U · kg-1 per time,3 times a week,subcutaneous injection.Treatment group was given levocarnitine 1.0 g per time,3 times a week,intravenous injection + Shengxuening tablets 0.5 g per time,tid,orally,on the basis of control group.Two groups were treated for 3 months.The clinical efficacy,the levels of serum ferritin (SF),transferrin saturation (TSAT),malondialdehyde (MDA),superoxide dismutase (SOD),glutathione peroxidase (GSH-Px),hematokrit (HCT) and hemoglobin (Hb),and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 93.33％ (14 cases/15 cases) and 60.00％ (9 cases/15 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:SF were (471.26 ± 43.46),(352.45 ± 33.27) ng · mL-1;TSAT were (34.75 ±3.86)％,(27.12 ±2.89)％;MDA were (9.47 ± 1.02),(12.37 ± 1.04) nmol · L-1;SOD were (73.05 ± 5.37),(62.12 ± 6.45) μg · mL-1;GSH-Px were (60.85 ± 5.48),(54.34 ± 5.39) U · L-1;HCT were (32.87 ± 2.74) ％,(25.63 ± 2.46) ％;Hb were (110.42 ± 11.23),(92.14 ± 10.04) g · L-1,all with significant difference(all P ＜ 0.05).The adverse drug reactions in treatment group were abdominal pain,fever,nausea and vomiting,which in control group were fever,nausea and vomiting.The incidences of adverse drug reactions in treatment and control groups were 20.00％ and 13.33％ without significant difference (P ＞ 0.05).Conclusion Levocamitine injection combined with Shengxuening tablets has a definitive clinical efficacy in the treatment of diabetic nephropathy peritoneal dialysis patients with renal anemia,which can significantly improve the levels of serum SF and TSAT and the antioxidant capacity,and reduce oxidative stress,without increasing the incidence of adverse drug reactions.
